Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial

Sefaxersen Phase III IgAN Interim Success

Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 24, 2026

Sentiment
25
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Positive Phase III interim data for sefaxersen strengthens the commercial outlook for Roche and Ionis in the IgAN market, potentially supporting upside in their shares and reinforcing the value of their licensing partnership. The readout raises competitive pressure on other IgAN drug developers and could shift investor expectations toward targeted complement-pathway therapies.

pharmaceuticals biotechnology healthcare

F. Hoffmann-La Roche — Genentech, a member of the Roche Group, and its partner Ionis Pharmaceuticals announced positive prespecified interim results from the ongoing Phase III IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint, with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction compared to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR). Sefaxersen is a once-monthly subcutaneous injection designed for self-administration and is the first mRNA-targeted therapy for IgAN, inhibiting complement factor B production in the liver. The safety and tolerability profile was consistent with previously reported data, with no new safety signals identified. Levi Garraway, F. Hoffmann-La Roche — Genentech chief medical officer, said the results show the clinical potential of sefaxersen to modify a key surrogate endpoint of kidney function and may offer a new treatment option to slow disease progression and reduce the long-term need for dialysis or kidney transplantation. Bonnie Schneider of the IgA Nephropathy Foundation noted the positive results represent the potential of targeted, convenient treatments. The IMAgINATION study will continue as a blinded study evaluating kidney function over two years via eGFR at week 105. F. Hoffmann-La Roche — Genentech plans to present interim data at an upcoming medical congress and share with health authorities to bring the treatment to patients as soon as possible. Roche licensed sefaxersen from Ionis for complement mediated diseases.

95 F. Hoffmann-La Roche — Genentech reported positive interim results
40 Roche licensed sefaxersen Ionis Pharmaceuticals
20 Levi Garraway stated results
10 Bonnie Schneider stated positive results
subs
F. Hoffmann-La Roche — Genentech is the lead sponsor of the IMAgINATION study and announced the positive interim results, strengthening its immunology pipeline and near-term commercial prospects in IgAN.
Importance 95.0 Sentiment 40.0
stock
Roche, as F. Hoffmann-La Roche — Genentech parent and licensor of sefaxersen from Ionis, stands to benefit from a potential new IgAN therapy that could add to its kidney disease franchise.
Importance 90.0 Sentiment 35.0
stock
Ionis licensed sefaxersen to Roche and stands to gain milestone and royalty revenue if the Phase III program succeeds, validating its antisense platform.
Importance 85.0 Sentiment 45.0
per
As F. Hoffmann-La Roche — Genentech chief medical officer, Garraway publicly endorsed the interim data, lending clinical credibility to the sefaxersen results.
Importance 40.0 Sentiment 10.0
per
As director and co-founder of the IgA Nephropathy Foundation, Schneider highlighted the unmet need and potential of targeted treatments, adding patient-advocacy support for sefaxersen.
Importance 20.0 Sentiment 5.0
ngo
The patient advocacy group voiced support for the positive IMAgINATION results, reinforcing the clinical relevance of sefaxersen for the IgAN community.
Importance 15.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.